Table 1 Baseline cognitive, neuropsychological and ADL function according to follow-up groups
Groups | n | MMSE ± SD* | ADAS-cog ± SD* | CDT** ± SD* | BI§ ± SD* | NPI‡ ± SD* |
|---|---|---|---|---|---|---|
Municipality | ||||||
Stimulation | 103 | 22.9 ± 4.6 | 18.9 ± 8.7 | 2.85 ± 1.2 | 6.08 ± 9·6 | 18.6 ± 2.6 |
Standard care | 77 | 23.5 ± 4.3 | 17.1 ± 7.0 | 2.84 ± 1.2 | 8.48 ± 10·5 | 18.6 ± 3.2 |
p-value | 0.34 | 0.22 | 0.96 | 0.12 | 0.995 | |
Drug | ||||||
Donepezil | 90 | 23.2 ± 4.2 | 18.6 ± 7.7 | 2.86 ± 1.1 | 7.48 ± 11·4 | 18.9 ± 2.1 |
Placebo | 90 | 23.1 ± 4.8 | 17.9 ± 8.4 | 2.84 ± 1.2 | 6.70 ± 8·9 | 18.4 ± 3.4 |
p-value | 0.83 | 0.55 | 0.95 | 0.61 | 0.29 | |
Combination | ||||||
Donepezil | 53 | 22.9 ± 4.5 | 19.2 ± 8.7 | 2.92 ± 1.1 | 6.29 ± 11·3 | 18.7 ± 2.3 |
+ stimulation | ||||||
Placebo | ||||||
+ Standard care | 40 | 23.3 ± 4.9 | 17.2 ± 8.0 | 2.93 ± 1.2 | 7.76 ± 10·4 | 18.1 ± 4.0 |
p-value | 0.64 | 0.24 | 0.998 | 0.53 | 0.45 | |
Head to head | ||||||
Stimulation therapy | 50 | 22.9 ± 4.7 | 18.5 ± 8.7 | 2.78 ± 1.3 | 5.85 ± 7·4 | 18.6 ± 2.8 |
Donepezil | 37 | 23.7 ± 3.7 | 17.6 ± 5.8 | 2.76 ± 1.3 | 9.29 ± 10·8 | 19.1 ± 1.8 |
p-value | 0.36 | 0.62 | 0.93 | 0.09 | 0.31 |